Talha Badar and Francesca Palandri/LinkedIn
Jun 12, 2026, 16:13
Talha Badar: Excellent Talk by Francesca Palandri on ET and PV at EHA 2026
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, shared a post on X:
“Excellent talk by Dr. Francesca Palandri on ET and PV at EHA 2026
Key takeaways:
Hydroxyurea remains the main 1st-line cytoreductive therapy, but care is increasingly individualized.
Emerging directions:
- Hepcidin modulation in PV, rusfertide and TMPRSS6 inhibitors
- CALR-targeted therapy, mAb and bispecific T-cell engagers
- Multidisciplinary care, including CV risk, fertility, dermatology, thrombosis, QoL
The future of MPN care is moving beyond count control toward disease biology, iron regulation, immune targeting, and patient-centered care.”
Stay updated with Hemostasis Today.
-
Sep 21, 2026, 00:29Iheanyichukwu Ike: Childhood Anaemia in Nigeria Through an Analysis of the 2018 NDHS
-
Sep 21, 2026, 00:27Nicole De Vita: The Global Burden of Iron Deficiency and Anemia in Women at SABM
-
Sep 21, 2026, 00:25Giuseppe Panuccio: IVUS and OCT Guidance Reduce MACE and Stent Thrombosis in Calcified Coronary Lesions
-
Sep 21, 2026, 00:23Parveen Yograj: Anemia in Older Adults 2026 – Don’t Call It “Just Old Age” and Find the Cause
-
Sep 21, 2026, 00:22Peter A. McCullough: McCullough Protocol Base Spike Detoxification and Oral Anticoagulation for Athletes
-
Sep 21, 2026, 00:20Rolando Claure: Apixaban Shows a More Favorable Benefit Risk Balance in Advanced CKD With AF
-
Sep 21, 2026, 00:14Kathaleen Schnur: HCWP’s Bubble Brigade at the 2026 Unite for Bleeding Disorders Walk
-
Sep 21, 2026, 00:13Amr Abouleish: Jehovah’s Witnesses Announce That Accepting Blood Is a Matter of Personal Conscience
-
Sep 21, 2026, 00:08Oluseyi Victor Owoeye: The Importance of Respecting Clients’ Beliefs, Values, Autonomy, and Human Dignity